Home/Serodus/Henrik Mordhorst

HM

Henrik Mordhorst

Chief Financial Officer

Therapeutic Areas

Nephrology Metabolic Disease

Serodus Pipeline

Drug	Indication	Phase
SER150	Diabetic Kidney Disease in Type 2 Diabetes	Phase 2
SER140	Diabetic Kidney Disease in Type 2 Diabetes	Phase 1

Leadership Team at Serodus

Dr. Eva Steiness

Chief Executive Officer

Business Development and Documentation

Søren Elmann Ingerslev

Chairman of the Board

Viggo G. Harboe

Lars Beck-Thomsen

Arnstein Endresen

View full Serodus profile